Cell entry and cAMP imaging of anthrax edema toxin.

EMBO J

Dipartimento di Scienze Biomediche ed Istituto CNR Neuroscienze, Padova, Italy.

Published: November 2006

The entry and enzymatic activity of the anthrax edema factor (EF) in different cell types was studied by monitoring EF-induced changes in intracellular cAMP with biochemical and microscopic methods. cAMP was imaged in live cells, transfected with a fluorescence resonance energy transfer biosensor based on the protein kinase A regulatory and catalytic subunits fused to CFP and YFP, respectively. The cAMP biosensor was located either in the cytosol or was membrane-bound owing to the addition of a tag determining its myristoylation/palmitoylation. Real-time imaging of cells expressing the cAMP biosensors provided the time course of EF catalytic activity and an indication of its subcellular localization. Bafilomycin A1, an inhibitor of the vacuolar ATPase proton pump, completely prevented EF activity, even when added long after the toxin. The time course of appearance of the adenylate cyclase activity and of bafilomycin A1 action suggests that EF enters the cytosol from late endosomes. EF remains associated to these compartments and its activity shows a perinuclear localization generating intracellular cAMP concentration gradients from the cell centre to the periphery.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1636612PMC
http://dx.doi.org/10.1038/sj.emboj.7601408DOI Listing

Publication Analysis

Top Keywords

anthrax edema
8
intracellular camp
8
time course
8
camp
6
activity
5
cell entry
4
entry camp
4
camp imaging
4
imaging anthrax
4
edema toxin
4

Similar Publications

Rational corticosteroids administration and antibiotic treatment is key to managing cutaneous anthrax.

BMC Infect Dis

October 2024

Department of Infectious Diseases, General Hospital of Ningxia Medical University, 804 Shengli Street, Xingqing District, Yinchuan, Ningxia, 750004, China.

Background: Anthrax is a global health concern, with cutaneous anthrax accounting for over 95% of cases and generally promising outcomes. Nonetheless, the absence of timely intervention can result in mortality rates of 10-40%. This research aims to explore the clinical presentations and phenotypic characteristics of cutaneous anthrax patients and evaluate the efficacy of various therapeutic approaches.

View Article and Find Full Text PDF
Article Synopsis
  • Anthrax is a rare disease caused by the bacterium Bacillus anthracis, with cutaneous anthrax being the most common form.
  • A case study of a nine-year-old boy with anthrax on his left eyelids showed rapid progression from a papular reaction to necrosis and eschar formation.
  • Treatment with antibiotics like ciprofloxacin and clindamycin led to a positive clinical response, highlighting the importance of early diagnosis and treatment to prevent complications like scarring and deformity.
View Article and Find Full Text PDF

Anthrax Toxin: Model System for Studying Protein Translocation.

J Mol Biol

April 2024

Department of Microbial Pathogenesis, School of Dentistry, University of Maryland, Baltimore, 650 W. Baltimore Street, Baltimore, MD 21201, USA. Electronic address:

Dedicated translocase channels are nanomachines that often, but not always, unfold and translocate proteins through narrow pores across the membrane. Generally, these molecular machines utilize external sources of free energy to drive these reactions, since folded proteins are thermodynamically stable, and once unfolded they contain immense diffusive configurational entropy. To catalyze unfolding and translocate the unfolded state at appreciable timescales, translocase channels often utilize analogous peptide-clamp active sites.

View Article and Find Full Text PDF

Early Circulating Edema Factor in Inhalational Anthrax Infection: Does It Matter?

Microorganisms

January 2024

Département des Maladies Infectieuses, Institut de Recherche Biomédicale des Armées, 91220 Brétigny-sur-Orge, France.

Anthrax toxins are critical virulence factors of and strains that cause anthrax-like disease, composed of a common binding factor, the protective antigen (PA), and two enzymatic proteins, lethal factor (LF) and edema factor (EF). While PA is required for endocytosis and activity of EF and LF, several studies showed that these enzymatic factors disseminate within the body in the absence of PA after intranasal infection. In an effort to understand the impact of EF in the absence of PA, we used a fluorescent EF chimera to facilitate the study of endocytosis in different cell lines.

View Article and Find Full Text PDF

Development of a New Cell-Based AP-1 Gene Reporter Potency Assay for Anti-Anthrax Toxin Therapeutics.

Toxins (Basel)

August 2023

Division of Biotechnology Review and Research II, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA.

Anthrax toxin is a critical virulence factor of . The toxin comprises protective antigen (PA) and two enzymatic moieties, edema factor (EF) and lethal factor (LF), forming bipartite lethal toxin (LT) and edema toxin (ET). PA binds cellular surface receptors and is required for intracellular translocation of the enzymatic moieties.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!